Zhejiang CONBA Pharmaceutical Co Ltd. Stock Analysis 600572.SS

Zhejiang Conba Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang and currently employs 7,826 full-time employees. The company went IPO on 2004-04-12. The Chinese medicine products includes prepared Chinese medicines, raw Chinese medicinal materials and processed Chinese medicinal herbs, Chinese medicine health products, and Chinese medicine extracts. The main products include the CONBA Changyanning series, the Jin Di compound houttuynia mixture series, the Qianliekang Prolean series, the Tianbaoning Ginkgo biloba series and Zhixinli musk heart-clearing pills, as well as Chinese medicinal herbs such as Astragalus membranaceus and Codonopsis pilosula. The firm also manufactures and sells specialty chemical preparations, raw materials, and nutritional supplements. The drugs are mainly used to treat cardiovascular, digestive, respiratory and urinary system diseases, as well as for anti-infection purposes.